JP2020524180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524180A5 JP2020524180A5 JP2020519012A JP2020519012A JP2020524180A5 JP 2020524180 A5 JP2020524180 A5 JP 2020524180A5 JP 2020519012 A JP2020519012 A JP 2020519012A JP 2020519012 A JP2020519012 A JP 2020519012A JP 2020524180 A5 JP2020524180 A5 JP 2020524180A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide
- position corresponding
- patient
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149977A JP7773014B2 (ja) | 2017-06-15 | 2023-09-15 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
| JP2025167674A JP2025188113A (ja) | 2017-06-15 | 2025-10-03 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520459P | 2017-06-15 | 2017-06-15 | |
| US62/520,459 | 2017-06-15 | ||
| PCT/US2018/037866 WO2018232313A2 (en) | 2017-06-15 | 2018-06-15 | Biomarkers for predicting tumor response to and toxicity of immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149977A Division JP7773014B2 (ja) | 2017-06-15 | 2023-09-15 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524180A JP2020524180A (ja) | 2020-08-13 |
| JP2020524180A5 true JP2020524180A5 (enExample) | 2021-07-29 |
| JP7352539B2 JP7352539B2 (ja) | 2023-09-28 |
Family
ID=64659596
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519012A Active JP7352539B2 (ja) | 2017-06-15 | 2018-06-15 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
| JP2023149977A Active JP7773014B2 (ja) | 2017-06-15 | 2023-09-15 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
| JP2025167674A Pending JP2025188113A (ja) | 2017-06-15 | 2025-10-03 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149977A Active JP7773014B2 (ja) | 2017-06-15 | 2023-09-15 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
| JP2025167674A Pending JP2025188113A (ja) | 2017-06-15 | 2025-10-03 | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11578371B2 (enExample) |
| EP (2) | EP3638308B1 (enExample) |
| JP (3) | JP7352539B2 (enExample) |
| AU (2) | AU2018283314B2 (enExample) |
| CA (1) | CA3067366A1 (enExample) |
| WO (1) | WO2018232313A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230103419A1 (en) * | 2020-02-12 | 2023-04-06 | Mira Dx, Inc. | Biomarkers for predicting toxicity of radiation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4988167A (en) | 1988-08-10 | 1991-01-29 | Fergason James L | Light blocking and vision restoration apparatus with glint control |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| US20030087818A1 (en) * | 2001-02-02 | 2003-05-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20060253263A1 (en) * | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
| US10471100B2 (en) | 2006-09-29 | 2019-11-12 | 4Life Patents, Llc | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2011131472A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| EP2850183A4 (en) | 2012-05-16 | 2016-02-10 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION |
| WO2014193937A1 (en) * | 2013-05-31 | 2014-12-04 | Yale University | The kras variant and response to cancer therapy |
| US20170115291A1 (en) * | 2014-05-28 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| EP3449015A1 (en) * | 2016-04-27 | 2019-03-06 | Mira DX, Inc. | Immune-based treatment of kras-variant cancer patients |
-
2018
- 2018-06-15 EP EP18817316.5A patent/EP3638308B1/en active Active
- 2018-06-15 JP JP2020519012A patent/JP7352539B2/ja active Active
- 2018-06-15 AU AU2018283314A patent/AU2018283314B2/en active Active
- 2018-06-15 EP EP24189386.6A patent/EP4491746A3/en active Pending
- 2018-06-15 WO PCT/US2018/037866 patent/WO2018232313A2/en not_active Ceased
- 2018-06-15 CA CA3067366A patent/CA3067366A1/en active Pending
- 2018-06-15 US US16/622,778 patent/US11578371B2/en active Active
-
2023
- 2023-02-02 US US18/163,723 patent/US12297509B2/en active Active
- 2023-09-15 JP JP2023149977A patent/JP7773014B2/ja active Active
-
2025
- 2025-04-30 US US19/195,308 patent/US20250305062A1/en active Pending
- 2025-08-28 AU AU2025223839A patent/AU2025223839A1/en active Pending
- 2025-10-03 JP JP2025167674A patent/JP2025188113A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chung et al. | Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma | |
| Skierucha et al. | Molecular alterations in gastric cancer with special reference to the early-onset subtype | |
| Sharma et al. | Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update | |
| JP2018536431A5 (enExample) | ||
| Florou et al. | Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib | |
| Lotem et al. | Runx3 in immunity, inflammation and cancer | |
| Zhao et al. | ARID2: a new tumor suppressor gene in hepatocellular carcinoma | |
| JP2012516682A5 (enExample) | ||
| Fayyaz et al. | Revolutionizing cancer treatment: the rise of personalized immunotherapies | |
| Rotellini et al. | Metastasizing maxillary ameloblastoma: report of a case with molecular characterization | |
| Tsukamoto et al. | Pancreatic desmoid-type fibromatosis with beta-catenin gene mutation—report of a case and review of the literature | |
| Kaemmerer et al. | Molecular classification of colorectal carcinomas: the genotype-to-phenotype relation | |
| Tatari et al. | Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population | |
| Ouyang et al. | Genetic characteristics of a patient with multiple primary cancers: A case report | |
| Terada | Protein expression and gene mutation status of KIT and PDGFRA in renal cell carcinoma | |
| Hoban et al. | Physical localisation of the breakpoints of a constitutional translocation t (5; 6)(q21; q21) in a child with bilateral Wilms' tumour. | |
| Ahmed et al. | Two unique cases of metastatic malignant melanoma of the gastrointestinal tract | |
| Kang et al. | ORAOV1 is a probable target within the 11q13. 3 amplicon in lymph node metastases from gastric adenocarcinoma | |
| Omatsu et al. | TNF-α-857C> T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma | |
| Purwar et al. | Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer | |
| Datkhile et al. | Role of p53 and p21 Polymorphisms in Cervical Cancer Risk among Rural Population of South-Western Maharashtra: A Case-Control Study. | |
| Dahy et al. | Small cells lung epidermoid carcinoma in a HTLV1-infected patient: case report and literature review | |
| Brune et al. | Genomic landscape of Hodgkin lymphoma. Cancers. 2021; 13: 682 | |
| JP7352539B2 (ja) | 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー | |
| Carneiro et al. | Genomic applications in pancreatic and gastric tumors |